Samidorphan clinical trials
Counted the way a researcher would: Samidorphan with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses samidorphan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 28 May 2021 · LYBALVI · NDA 213378 (FDA, Drugs@FDA; in a combination)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 1
Alkermes, Inc. (15) · National Institute on Drug Abuse (NIDA) (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Opioid antagonists source
Studies
Open first, then newest update. How each study uses samidorphan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831CompletedPhase 3Alkermes, Inc.NCT03201757Written as ALKS 3831
- Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderCompletedPhase 3Alkermes, Inc.NCT03187769Written as ALKS 3831
- A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use DisorderCompletedPhase 2Alkermes, Inc.NCT02161718Written as Samidorphan + olanzapine (ALKS 3831)
- A Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 2Alkermes, Inc.NCT01903837Written as Samidorphan (Low Dose)
- A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 3Alkermes, Inc.NCT02873208Written as ALKS 3831
- A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)CompletedPhase 3Alkermes, Inc.NCT02694328Written as ALKS 3831
- A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With SchizophreniaCompletedPhase 3Alkermes, Inc.NCT02669758Written as ALKS 3831
- An Insulin Sensitivity Study in Healthy SubjectsCompletedPhase 1Alkermes, Inc.NCT02922426Written as ALKS 3831
- Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy AdultsCompletedPhase 1National Institute on Drug Abuse (NIDA)NCT01046539Written as RDC-0313 + Buprenorphine
- A Phase 1 Safety Study in Adults With SchizophreniaCompletedPhase 1Alkermes, Inc.NCT02804568Written as ALKS 3831
- A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male VolunteersCompletedPhase 1Alkermes, Inc.NCT02504463Written as Samidorphan IV
- A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid UsersCompletedPhase 1Alkermes, Inc.NCT02218021Written as Samidorphan
- ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With CocaineCompletedPhase 1Alkermes, Inc.NCT01366001Written as ALKS 33-BUP
- ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating DisorderCompletedPhase 2Alkermes, Inc.NCT01098435Written as RDC-0313 (ALKS 33)
- ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol DependenceCompletedPhase 2Alkermes, Inc.NCT00981617Written as ALKS33 (RDC-0313) (1 mg)
- ALK33-001: A Study of RDC-0313 Administered to Healthy AdultsCompletedPhase 1Alkermes, Inc.NCT00800319Written as RDC-0313
Codes
What other systems call samidorphan · ClinicalTrials.gg INT000423
- MeSH (NLM) C000606131samidorphanOne source NLM
- UNII (FDA) 7W2581Z5L8SAMIDORPHANConfirmed FDA, NLM, Wikidata
- RxNorm 2559612One source FDA
- Wikidata Q7409428samidorphanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152293SamidorphanOne source FDA
- DrugBank DB12543One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000606131 | samidorphan | One source NLM |
| UNII (FDA) | 7W2581Z5L8 | SAMIDORPHAN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2559612 | — | One source FDA |
| Wikidata | Q7409428 | samidorphan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152293 | Samidorphan | One source FDA |
| DrugBank | DB12543 | — | One source Wikidata |
Also registered as samidorphan l-malate (UNII 0AJQ5N56E0 · RxNorm 2570387).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.